The role of IL-37 in skin and connective tissue diseases

Pan, Yu; Wen, Xiang; Hao, Dan; Wang, Yujia; Wang, Lian; He, Gu; Jiang, Xian

doi:10.1016/j.biopha.2019.109705

Cited by 46 publications

(45 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Along with other inflammatory diseases, IL-37 has also found to be elevated in AD patients and also correlates with disease severity [ 41 ]. The dual functionality of IL-37 helps to inhibit cytokines that promote inflammation (IL-1α, IL-1 β, IL-1Ra, IL-6, IL-8, IL-17, IL-23, TNF-α, and IFN-γ) and stimulates expression of transcription growth factor (TGF)-β1 and nitric oxide [ 11 ]. It also exerts anti-inflammatory effects by regulating and shifting kinases toward anti-inflammatory pathways [ 11 ].…”

Section: Reviewmentioning

confidence: 99%

“…The dual functionality of IL-37 helps to inhibit cytokines that promote inflammation (IL-1α, IL-1 β, IL-1Ra, IL-6, IL-8, IL-17, IL-23, TNF-α, and IFN-γ) and stimulates expression of transcription growth factor (TGF)-β1 and nitric oxide [ 11 ]. It also exerts anti-inflammatory effects by regulating and shifting kinases toward anti-inflammatory pathways [ 11 ]. Some evidence also links IL-37 to interacting with autophagy.…”

Section: Reviewmentioning

confidence: 99%

“…Biologics currently on the market target IL-4 and IL-13 for moderate to severe AD. It can be hypothesized that IL-37 can be used as a biologic to treat AD through inhibition of IL-4 and IL-13 [ 11 ]. IL-37 also is implicated in the inflammatory process of other disease processes like psoriasis, psoriatic arthritis, atherosclerotic process like lipid metabolism and apoptosis [ 11 ].…”

Section: Reviewmentioning

confidence: 99%

“…It can be hypothesized that IL-37 can be used as a biologic to treat AD through inhibition of IL-4 and IL-13 [ 11 ]. IL-37 also is implicated in the inflammatory process of other disease processes like psoriasis, psoriatic arthritis, atherosclerotic process like lipid metabolism and apoptosis [ 11 ]. This suggests that IL-37 is a potential target of therapy for various diseases due to its great subjugation of inflammatory processes and regulation in immunity.…”

Section: Reviewmentioning

confidence: 99%

“…Th17 and Th9 cytokines (IL-17, IL-12/IL-23, IL-9) seem to predominate intrinsic AD [ 8 ]. IL-37 is a noteworthy cytokine because it is found to inhibit IL-1, IL-6, IL-8, IL-17, and IL-23 which are known pro-inflammatory cytokines [ 11 ]. It has been suggested by Lee et al that IL-18 is known to activate mast cells to release chymase which cleave pro-IL-18 to accelerate the inflammatory process in AD lesions and hence release of cytokines [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Review of Prominent Cytokines as Superior Therapeutic Targets for Moderate-to-Severe Atopic Dermatitis

Hassan

Luvsannyam

Patel

et al. 2020

Cureus

View full text Add to dashboard Cite

Cytokines predominate the inflammatory pathways in diseases like rhinitis, asthma, and atopic dermatitis. Corticosteroids and immunosuppressants are presently the mainstays of treatment for patients with moderate-to-severe disease, but often accompany a poor side effect profile. In this review, we attempt to consolidate current data on various interleukins (IL) that participate in the pathogenesis of atopic dermatitis (AD) to further improve therapeutic strategies. For now, dupilumab is the most accepted biologic to be registered for treatment for moderate-to-severe disease. Recently, IL-37, IL-13, IL-26, IL-17 & IL-31/33 axis as well as proteins like thymic stromal lymphopoietin (TSLP) show promising results as future therapeutic targets because of their important role in the pathogenesis of AD. However, further studies are required to clarify the safety and efficacy of these interventions compared to current treatment modalities but it is worthwhile to pursue research into biologics as a more successful treatment option for moderate-to-severe AD.

show abstract

Section: Reviewmentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Review of Prominent Cytokines as Superior Therapeutic Targets for Moderate-to-Severe Atopic Dermatitis

Hassan

Luvsannyam

Patel

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

Neuroimmune interactions in painful TMD: Mechanisms and treatment implications

Zhou

Xiong

et al. 2021

Journal of Leukocyte Biology

View full text Add to dashboard Cite

The underlying mechanisms and treatment of painful temporomandibular disorders (TMDs) are important but understudied topics in craniofacial research. As a group of musculoskeletal diseases, the onset of painful TMD is proved to be a result of disturbance of multiple systems. Recently, emerging evidence has revealed the involvement of neuroimmune interactions in painful TMD. Inflammatory factors play an important role in peripheral sensitization of temporomandibular joint (TMJ), and neurogenic inflammation in turn enhances TMJs dysfunction in TMD. Furthermore, centralized neuroimmune communications contribute to neuron excitability amplification, leading to pain sensitization, and is also responsible for chronic TMD pain and other CNS symptoms. Therapeutics targeting neuroimmune interactions may shed light on new approaches for treating TMD. In this review, we will discuss the role of neuroimmune interactions in the onset of painful TMD from the peripheral and centralized perspectives, and how understanding this mechanism could provide new treatment options. Insights into the neuroimmune interactions within TMJs and painful TMD would broaden the knowledge of mechanisms and treatments of this multifactorial disease.

show abstract